Sorrento Therapeutics (NASDAQ: SRNE) is putting on a volatility show this week. The bulls were leading the charge at the start of the week but took a big rest on Wednesday, which saw SRNE pullback by 12%. All bullish hope seemed lost. However, today the FDA gave Sorrento the green light to begin phase I […]